What are the clinical findings in Systemic Lupus Erythematosus (SLE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clinical Findings in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus presents with diverse clinical manifestations affecting multiple organ systems, with mucocutaneous, musculoskeletal, renal, and neuropsychiatric manifestations being the most common findings that significantly impact morbidity and mortality. 1, 2

Mucocutaneous Manifestations

  • LE-specific lesions:

    • Acute cutaneous LE (malar/butterfly rash) - present in 37.7% of patients 3
    • Subacute cutaneous LE
    • Chronic cutaneous LE (discoid lupus) - present in 17.6% of patients 3
    • Intermittent cutaneous LE
  • Other skin findings:

    • Photosensitivity - present in 35.1% of patients 3
    • Hair loss (alopecia) - present in 39.3% of patients 3
    • Oral/nasal ulcers
    • Raynaud's phenomenon
  • Diagnostic considerations:

    • Skin biopsy may be necessary for definitive diagnosis
    • Follow-up biopsy recommended if lesions change morphology or fail to respond to treatment 1

Musculoskeletal Manifestations

  • Arthralgia (joint pain) - present in 68.8% of patients 3
  • Myalgia (muscle pain) - present in 55.7% of patients 3
  • Non-erosive arthritis - present in 48.3% of patients 3
  • Myositis - present in 2.5% of patients 3
  • Avascular necrosis - present in 2% of patients 3
  • Tendon abnormalities - present in 0.3% of patients 3

Renal Manifestations

  • Lupus nephritis occurs in approximately 40% of patients 4
  • Clinical findings include:
    • Proteinuria
    • Hematuria
    • Cellular casts
    • Elevated serum creatinine
    • Hypertension
  • Renal disease is associated with:
    • Flare rate of 0.1-0.2 flares/patient/year
    • Risk of doubling serum creatinine: 7.4-8.5% at 5 years, 14.3-18.2% at 10 years 1
    • 10% of patients with lupus nephritis develop end-stage kidney disease after 10 years 4

Neuropsychiatric Manifestations

  • Common neuropsychiatric syndromes include:
    • Headache
    • Mood disorders
    • Seizures
    • Cognitive impairment (memory, attention, concentration, word-finding difficulties)
    • Cerebrovascular disease 1
  • Assessment requires:
    • Clinical history
    • Neuroimaging
    • Cerebrospinal fluid analysis
    • Electroencephalogram
    • Neuropsychological testing
    • Nerve conduction studies 2

Constitutional Symptoms

  • Fatigue - present in 35.2% of patients 3
  • Fever
  • Weight changes - present in 13.4% of patients 3
  • Constitutional symptoms overall present in 48.7% of patients 3

Hematologic Abnormalities

  • Anemia (severe anemia associated with organ involvement and worse prognosis)
  • Thrombocytopenia (associated with renal disease and disease progression)
  • Leukopenia/lymphopenia (associated with increased infection risk) 1

Serological Findings

  • Anti-dsDNA antibodies (correlate with disease activity, especially renal disease)
  • Low complement levels (C3, C4)
  • Antiphospholipid antibodies (associated with thrombotic manifestations)
  • C-reactive protein (CRP) is typically not elevated in SLE flares; significant elevation (>50 mg/L) suggests superimposed infection 1

Cardiovascular Findings

  • Accelerated atherosclerosis
  • Pericarditis
  • Myocarditis
  • Libman-Sacks endocarditis
  • Patients have almost 5-fold increased risk of death compared to general population 1, 2

Ocular Manifestations

  • Retinal vasculitis
  • Optic neuritis
  • Antimalarial-induced retinopathy (rare complication of treatment, 0.5% incidence) 1

Pulmonary Manifestations

  • Pleuritis
  • Pneumonitis
  • Pulmonary hypertension
  • Interstitial lung disease
  • Shrinking lung syndrome

Common Comorbidities

  • Infections (major cause of morbidity and mortality)
  • Hypertension
  • Coronary heart disease
  • Diabetes mellitus
  • Dyslipidemia
  • Osteoporosis
  • Avascular bone necrosis
  • Increased risk for certain cancers (non-Hodgkin's lymphoma, lung cancer, hepatobiliary cancer) 1, 2

Clinical Pearls and Pitfalls

  • SLE predominantly affects females (90% of cases) 4
  • Disease presentation varies widely in severity from mild rashes and arthritis to severe organ and life-threatening manifestations 5
  • Elevated CRP with normal ESR suggests infection rather than SLE flare 1
  • Regular monitoring of disease activity using validated indices (SLEDAI, BILAG) is essential 2
  • Early diagnosis and treatment significantly improve outcomes and reduce organ damage

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Systemic Lupus Erythematosus Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations.

Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2019

Research

Systemic lupus erythematosus: an overview.

Social work in health care, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.